• Regulatory NewsRegulatory News

    OPQ touts progress on quality management maturity, KASA in annual report

    The US Food and Drug Administration’s (FDA) Office of Pharmaceutical Quality (OPQ) reported that progress has been made over the past year in advancing its quality management maturity initiative and in its quality assessment review process in its 2022 annual report.   The report also describes progress made in other areas under OPQ’s remit. The office’s previous two reports focused largely on its COVID-19 response. (RELATED:  FDA’s OPQ reports on drug quality efforts ...
  • Regulatory NewsRegulatory News

    Califf: Advisory committee meeting structure needs an overhaul

    The US Food and Drug Administration’s (FDA) advisory committee system needs to be changed to allow fuller and more comprehensive discussion of the issues surrounding the approval of a medical product under review and should be less about the outcome, said FDA Commissioner Robert Califf.   Califf made these remarks at the Biopharma Congress meeting in Washington, DC on 13 February. During the meeting, which was moderated by Kate Rawson of Prevision Policy, Califf also r...
  • Regulatory NewsRegulatory News

    Top FDA official interested in ‘Project Orbis’ for cell and gene therapies

    A top official from the US Food and Drug Administration (FDA) said he wants to see something similar to the agency’s Project Orbis program developed for cell and gene therapies, as the involvement of other “high-income countries” could help attract developers, asserted Peter Marks, director of FDA’s Center for Biologics Evaluation and Research (CBER), at the Biopharma Congress on 13 February.   At the meeting, FDA officials offered their perspectives on other policy ar...
  • Regulatory NewsRegulatory News

    FDA reprimands two device firms for multiple violations

    The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) recently warned two foreign medical device companies – a manufacturer of microcatheters and a laparoscopic instrument maker – for issues including failing to follow through on corrective actions plans, not seeking necessary approval for a new device use and a lax materials testing program.   The targets of the warning letters, which were posted to FDA’s website on 7 February, ...
  • Regulatory NewsRegulatory News

    FDA officials offer advice on gene therapy trials

    Officials from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) asserted that the duration of clinical trials for gene therapies depends on the nature of the disease being treated, and that diseases that are more progressive and have a rapid onset may involve shorter trials.   This was one of the learnings imparted by officials during a 7 February virtual town hall meeting to...
  • Regulatory NewsRegulatory News

    DSCSA: New interoperability ‘blueprint’ released

    With less than a year remaining before the Drug Supply Chain Security Act (DSCSA) takes full effect, an industry consortium has published new chapters of a guide to help drugmakers and their trading partners establish the necessary electronic systems to track their products through the supply chain.   The new chapters complement an earlier guide on understanding the compliance and baseline business requirements on trading of information, which was released in July 20...
  • Regulatory NewsRegulatory News

    EMA wants participants to serve on clinical trial multistakeholder forum

    The European Medicines Evaluation Agency (EMA), the Heads of Medicines Agencies (HMA), and the European Commission are calling for representatives from the research community, pharmaceutical sponsors, academics and regulators to participate in a new multistakeholder platform (MSP) or forum to share and implement ideas for improving clinical trials in the EU.   The call for participation is being launched under last year’s EC-HMA-EMA initiative Accelerating Clinical Tri...
  • Regulatory NewsRegulatory News

    FDA draft guidance addresses clinical development of drugs to treat early Lyme disease

    The US Food and Drug Administration (FDA) Center for Drug Evaluation Research (CDER) has issued a draft guidance to help sponsors develop new drugs to treat the early stages of Lyme disease.   The draft addresses criteria for clinical trial enrollment, efficacy endpoints, and clinical microbiology considerations for treating early stages of the disease when manifested by erythema migrans (EM), a rash that is often one of the first symptoms.   In North America, Lyme...
  • Regulatory NewsRegulatory News

    FDA draft guidance addresses use of external controls to assess effectiveness of new drugs and biologics

    The FDA Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) have issued draft guidance describing sponsors can leverage external controls, such as use data from registries and electronic health records, in lieu of data from randomized controlled trials (RCTs) to demonstrate the safety and effectiveness of new drugs and biologics.   The draft guidance also describes how sponsors can communicate with FDA on using dat...
  • Regulatory NewsRegulatory News

    FDA releases FY 2022 generic drug research summary

    The US Food and Drug Administration’s (FDA) Office of Generic Drugs (OGD) on Tuesday released a report summarizing its research activities in fiscal year 2022 in 13 different scientific areas under the Generic Drug User Fee Amendments (GDUFA III).   The research generated from the program enabled FDA to issue 177 new and revised product-specific guidances (PSGs), 59 of which were for complex products, according to the summary.   “The recommendations in many of th...
  • Regulatory NewsRegulatory News

    FDA issues draft guidance on developing drugs for acromegaly

    The US Food and Drug Administration (FDA) has issued a draft guidance to assist sponsors develop acromegaly treatments for patients who have either not responded to surgery or are in poor health.   Acromegaly is a chronic, rare disease in adults caused by excess growth hormone that can cause enlarged hands and feet, among other symptoms. The most common cause stems from a growth hormone that stimulates hepatic overproduction of insulin-like growth factor-1 (IGF-1).  ...
  • Regulatory NewsRegulatory News

    FDA announces FY 2023-2027 BsUFA science and research priorities

    The US Food and Drug Administration (FDA) on Thursday released a roadmap on its science and research priorities for fiscal years 2023-2027 to spur the development of biosimilars and interchangeable products.   Under the Biosimilar User Fee Amendments (BsuFA) III program, FDA has offered $5 million in funding for several research proposals under the regulatory science pilot program (RELATED: FDA offers funding for biosimilar regulatory science pilot , Regulatory Foc...